NovaBridge Biosciences NBP
1.38
(0.07)
(4.83%)
as of 25 Sep
- Market cap
- $172.8M
- P/E
- 0.0×
Follow NBP
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | 9.73 | 1.37 | 15.05 | 16.47 | 6.19 | 6.19 | 6.19 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (1.03) | (2.18) | (24.30) | 58.65 | (0.35) | (0.35) | (0.35) |
P/B ratio |
— | — | 0.78 | 0.83 | 5.19 | 4.52 | 0.23 | 0.23 | 0.23 |
Price to Tangible BV |
— | — | 0.84 | 0.91 | 5.53 | 4.76 | 0.30 | 0.30 | 0.30 |
EV/Sales |
— | — | (5.94) | (0.61) | 12.40 | 13.38 | (16.57) | (16.57) | (16.57) |
EV/EBITDA |
— | — | 0.00 | 0.00 | 26.06 | 26.98 | 1.50 | 1.50 | 1.50 |
EV/Operating CF |
— | — | 0.27 | 0.33 | (12.70) | (19.44) | 0.00 | 0.00 | 0.00 |
EV/FCF |
— | — | 0.27 | 0.33 | (12.70) | (19.44) | 0.00 | 0.00 | 0.00 |
Quick Ratio |
7.84 | 20.51 | 5.36 | 4.72 | 6.91 | 8.54 | 3.88 | 5.66 | 3.50 |
Current Ratio |
8.09 | 20.90 | 5.67 | 4.78 | 7.66 | 9.28 | 4.12 | 5.88 | 3.54 |
Net Debt/EBITDA |
2.26 | 3.44 | 4.33 | 1.83 | 2.04 | (26.73) | 0.76 | (2.60) | (0.91) |
Debt/Assets |
0.00% | 0.00% | 1.14% | 1.25% | 2.01% | 0.21% | 6.80% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.00 | 0.09 | (3.21) | (3.08) |
Asset Turnover |
0.00 | 0.00 | 0.00 | (0.04) | 0.01 | 0.39 | 0.03 | 0.00 | 0.01 |
Operating CF/Net income |
0.45 | 2.37 | 0.35 | 0.44 | 0.42 | 0.92 | 0.58 | 0.70 | 0.85 |
Capex/Depreciation |
0.05 | 0.01 | (0.15) | (0.72) | (0.88) | (0.35) | (0.78) | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (21.42%) | (10.02%) | (62.52%) | (63.92%) | (46.37%) | 13.71% | (826.99%) | 65.76% | 47.67% | |
| (19.56%) | (7.64%) | (43.30%) | (49.47%) | (39.56%) | 11.83% | (170.93%) | 0.00% | (17.53%) | |
ROIC |
(293.14%) | (115.77%) | 0.00% | 0.00% | (327.57%) | 11.43% | (415.21%) | 0.00% | 0.00% |
Return on Tangible Assets |
(24.25%) | (13.20%) | (75.94%) | (85.60%) | (55.47%) | 9.83% | (139.96%) | (24.32%) | (55.39%) |
Average Days of Receivables |
— | — | 0.00 | (54.26) | 137.17 | 30.88 | 679.40 | 420.54 | 134.44 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 3,393.67% | (408.41%) | 1,377.98% | 63.83% | 2,801.53% | 792.15% | 2,311.16% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 4,455.70% | (368.18%) | 1,022.38% | 26.09% | 2,181.97% | 110.91% | 205.97% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.05 | 0.07 | 0.05 | 0.04 | 0.18 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1,620.09% | (161.19%) | 691.41% | 31.99% | 1,223.04% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 1.08 | 1.03 | 0.16 | 0.18 | 3.16 | 3.16 | 3.16 |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (199.40%) | (79.95%) | (5.32%) | (35.44%) | (140.48%) | (140.48%) | (140.48%) |
Free Cash Flow Yield |
— | — | (227.29%) | (133.97%) | (6.48%) | (4.18%) | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.01 | (0.39) | 0.18 | 4.05 | 1.34 | 0.14 | 0.03 |
Operating CF per Share |
(0.22) | (0.65) | (0.87) | (1.94) | (2.01) | 1.14 | (38.85) | (0.73) | (0.64) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.08) | (0.06) | (0.02) | (0.55) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.21) | (0.65) | (0.88) | (2.02) | (2.07) | 1.12 | (39.40) | (0.73) | (0.64) |
Cash per Share |
2.20 | 2.14 | 3.75 | 6.23 | 8.84 | 12.59 | 54.85 | 4.75 | 1.79 |
Shareholders Equity per Share |
2.41 | 2.48 | 2.91 | 5.11 | 9.42 | 14.78 | 59.43 | (2.39) | (0.79) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.41 | 2.48 | 2.91 | 5.11 | 9.42 | 14.78 | 59.43 | (2.39) | (0.79) |
Free Cash Flow |
(20.56) | (52.65) | (72.86) | (166.54) | (157.40) | 65.22 | (126.44) | (42.42) | (37.31) |
Working Capital |
190.63 | 168.24 | 271.77 | 415.87 | 652.44 | 730.66 | 148.09 | 246.25 | 76.24 |
Capital Expenditures |
0.04 | 0.01 | (0.16) | (6.64) | (4.70) | (1.23) | (1.76) | (2.18) | (3.01) |
Net Current Asset Value |
187.94 | 165.17 | 203.57 | 357.06 | 586.90 | 710.66 | 136.65 | (188.14) | (50.34) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.25 | (0.21) | 0.34 | 0.01 | 0.41 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | (32,868.51%) | 1,131.63% | (2,648.74%) | 30.53% | (4,950.29%) | (749.02%) | (2,580.85%) |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
6.11 | 4.87 | 0.60 | 1.05 | 0.75 | 0.92 | 0.52 | 0.25 | 0.07 |
Cash ROIC |
(4.69%) | (14.12%) | (13.33%) | (17.88%) | (11.38%) | 3.91% | (33.62%) | (7.97%) | (20.37%) |
Accounts Receivable Turnover |
— | — | 0.00 | (6.45) | 1.10 | 16.88 | 0.50 | 1.63 | 0.34 |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 214.11 | — | — | — | — |
Average Receivables |
— | — | — | 4.98 | 12.60 | 14.01 | 8.69 | 5.00 | 5.00 |
Average Assets |
236.60 | 290.80 | 479.77 | 734.79 | 924.82 | 610.14 | 124.79 | 0.00 | 251.76 |
Average Common Equity |
216.05 | 221.87 | 332.24 | 568.70 | 788.95 | 526.55 | 25.79 | (92.57) | (92.57) |
Columns are period end dates